Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4C | Q9H3R0 | 16/20 | 0.59 |
| ▸ | KDM6B | O15054 | 9/20 | 0.59 |
| ▸ | KDM4D | Q6B0I6 | 5/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.59 |
| ▸ | KDM4A | O75164 | 2/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 1/20 | 0.59 |
| ▸ | THRB | P10828 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.59 |
| ▸ | ASPH | Q12797 | 2/20 | 0.47 |
| ▸ | KDM8 | Q8N371 | 2/20 | 0.47 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.44 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.44 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.44 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29578794 | 1.00 | KDM4C (0.59) | KDM4CKDM6BKDM4DKDM4EKDM4A | |
| Hydrochloric Acid SCHEMBL1027857 | 0.98 | KDM4C (0.57) | KDM4CKDM6BKDM4DKDM4EKDM4A | |
| Nitrous Acid SCHEMBL28904582 | 0.92 | KDM4C (0.52) | KDM4CKDM6BKDM4DKDM4EKDM4A | |
| SCHEMBL8686759 | 0.88 | ROCK2 (0.47) | KDM4CKDM6BKDM4DKDM4EKDM4A | |
| SCHEMBL229353 | 0.83 | KDM4C (0.53) | KDM4CKDM6BKDM4DKDM4EKDM4A | |
| SCHEMBL30316868 | 0.83 | KDM4C (0.53) | KDM4CKDM6BKDM4DKDM4EKDM4A | |
| SCHEMBL25201864 | 0.81 | KDM4C (0.42) | KDM4CKDM6BKDM4DKDM4EKDM4A | |
| SCHEMBL459712 | 0.81 | LOXL2 (0.44) | KDM4CKDM6BKDM4DKDM4EKDM4A | |
| SCHEMBL724581 | 0.81 | ALDH1A1 (0.52) | KDM4CKDM6BKDM4DKDM4EKDM4A | |
| SCHEMBL2618803 | 0.81 | TDP1 (0.55) | KDM4CKDM6BKDM4DKDM4EKDM4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 702 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122037226-A | Bimetallic-organic framework material for trapping trifluoromethane, preparation method thereof and adsorbent based on bimetallic-organic framework material | 西安交通大学 | 2026-05-15 | — | — | CN | claimed |
| CN-118420919-A | Metal organic framework material with trivalent boron blocked Lewis acid-base pair with fixed structures at two ends, preparation method and application thereof | 武汉大学 | 2024-08-02 | — | — | CN | claimed |
| CN-118007162-A | Preparation method of carbon dioxide electro-reduction catalyst | 中汽研汽车检验中心（天津）有限公司 | 2024-05-10 | — | — | CN | claimed |
| CN-116936810-B | Positive pole piece of sodium ion battery and sodium ion battery | 天鹏锂能技术(淮安)有限公司 | 2023-12-12 | — | — | CN | claimed |
| CN-116936810-A | Positive pole piece of sodium ion battery and sodium ion battery | 天鹏锂能技术(淮安)有限公司 | 2023-10-24 | — | — | CN | claimed |
| CN-116574270-A | Cobalt-based metal organic framework material and preparation method and application thereof | 吉林大学 | 2023-08-11 | — | — | CN | claimed |
| CN-111072987-B | Two fluorinated metal organic framework materials, preparation and low-carbon hydrocarbon separation application thereof | 北京工业大学 | 2022-02-15 | — | — | CN | claimed |
| CN-111072987-A | Two fluorinated metal organic framework materials, preparation and low-carbon hydrocarbon separation application thereof | 北京工业大学 | 2020-04-28 | — | — | CN | claimed |
| CN-110818629-A | Method for synthesizing fluoroisonicotinic acid derivative | 杭州勇诚睿生物科技有限公司 | 2020-02-21 | — | — | CN | claimed |
| US-20150005320-A9 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2015-01-01 | — | — | US | claimed |
| EP-1651232-A4 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP (US) | 2007-06-06 | — | — | EP | claimed |
| EP-1653968-A4 | METHOD FOR MODULATING CALCIUM ION-RELEASE-ACTIVATED CALCIUM ION CHANNELS | SYNTA PHARMACEUTICALS CORP (US) | 2006-09-06 | — | — | EP | claimed |
| CN-1826121-A | Method for regulating and controlling calcium ion release to activate calcium ion channel | SYNTA PHARMACEUTICALS CORP (US) | 2006-08-30 | — | — | CN | claimed |
| CN-1826120-A | Compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP (US) | 2006-08-30 | — | — | CN | claimed |
| EP-1653968-A2 | METHOD FOR MODULATING CALCIUM ION-RELEASE-ACTIVATED CALCIUM ION CHANNELS | Synta Pharmaceuticals Corporation (US) | 2006-05-10 | — | — | EP | claimed |
| EP-1651232-A2 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | Synta Pharmaceuticals Corporation (US) | 2006-05-03 | — | — | EP | claimed |
| US-20050148633-A1 | Calcium channel blockers and releasing ions for prodrugs | SYNTA PHARMACEUTICALS CORP. | 2005-07-07 | — | — | US | claimed |
| US-20050107436-A1 | phenyl and pyridyl derivatives such as 3-Fluoro-N-(2'-trifluoromethyl-biphenyl-4-yl)-isonicotinamide, used as immunosuppressants for the treatmet or prevent inflammatory and immune disorders | SYNTA PHARMACEUTICALS CORP. | 2005-05-19 | — | — | US | claimed |
| WO-2005009954-A2 | METHOD FOR MODULATING CALCIUM ION-RELEASE-ACTIVATED CALCIUM ION CHANNELS | SYNTA PHARMACEUTICALS, CORP. (US) | 2005-02-03 | — | — | WO | claimed |
| WO-2005009539-A2 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS, CORP. (US) | 2005-02-03 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050148633-A1 | Calcium channel blockers and releasing ions for prodrugs | ORAI1, CACNA1C, CACNA1F | KDM4C 1567/4885KDM6B 1768/4885KDM4D 2708/4885 |
| US-20150005320-A9 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | CXCR2, CXCL8, CCR9 | KDM4C 3557/4885KDM6B 2111/4885KDM4D 3444/4885 |
| US-20050107436-A1 | phenyl and pyridyl derivatives such as 3-Fluoro-N-(2'-trifluoromethyl-biphenyl-4-yl)-isonicotinamide, used as immunosuppressants for the treatmet or prevent inflammatory and immune disorders | TPMT, PTPN3, FKBP3 | KDM4C 1774/4885KDM6B 1012/4885KDM4D 903/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.